WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H319896
CAS#: 496054-87-6
Description: Radiprodil, also known as RGH-896, is an orally active and selective NMDA receptors antagonist which was evaluated as potential treatmen of neuropathic pain associated with diabetic peripheral neuropathy (DPNP). Treatment with radiprodil did not show statistically significant or clinically meaningful reductions in mean daily pain scores, the primary endpoint, compared to placebo for any of the dosages studied. Based on preclinical pharmacology Radiprodil was a potential therapeutic agent in treatment of neuropathic pain and possibly other chronic pain conditions.
Hodoodo Cat#: H319896
Name: Radiprodil
CAS#: 496054-87-6
Chemical Formula: C21H20FN3O4
Exact Mass: 397.14
Molecular Weight: 397.410
Elemental Analysis: C, 63.47; H, 5.07; F, 4.78; N, 10.57; O, 16.10
Synonym: RGH-896; RGH896; RGH 896; Radiprodil
IUPAC/Chemical Name: 2-(4-((4-Fluorophenyl)methyl)piperidin-1-yl)-2-oxo-N-(2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)acetamide
InChi Key: GKGRZLGAQZPEHO-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H20FN3O4/c22-15-3-1-13(2-4-15)11-14-7-9-25(10-8-14)20(27)19(26)23-16-5-6-17-18(12-16)29-21(28)24-17/h1-6,12,14H,7-11H2,(H,23,26)(H,24,28)
SMILES Code: O=C(NC1=CC=C2NC(OC2=C1)=O)C(N3CCC(CC4=CC=C(F)C=C4)CC3)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 397.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Fernandes A, Wojcik T, Baireddy P, Pieschl R, Newton A, Tian Y, Hong Y,
Bristow L, Li YW. Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor
open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol.
2015 Nov 5;766:1-8. doi: 10.1016/j.ejphar.2015.08.044. Epub 2015 Aug 29. PubMed
PMID: 26325093.
2: Michel A, Downey P, Van Damme X, De Wolf C, Schwarting R, Scheller D.
Behavioural Assessment of the A2a/NR2B Combination in the Unilateral
6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of
Non-Dopaminergic Drugs. PLoS One. 2015 Aug 31;10(8):e0135949. doi:
10.1371/journal.pone.0135949. eCollection 2015. PubMed PMID: 26322641; PubMed
Central PMCID: PMC4555651.
3: Michel A, Downey P, Nicolas JM, Scheller D. Unprecedented therapeutic
potential with a combination of A2A/NR2B receptor antagonists as observed in the
6-OHDA lesioned rat model of Parkinson's disease. PLoS One. 2014 Dec
16;9(12):e114086. doi: 10.1371/journal.pone.0114086. eCollection 2014. PubMed
PMID: 25513815; PubMed Central PMCID: PMC4267740.
